Tadashi Watabe1,2, Yuwei Liu3, Kazuko Kaneda-Nakashima2,4, Yoshifumi Shirakami2, Thomas Lindner5, Kazuhiro Ooe3,2, Atsushi Toyoshima2,4, Kojiro Nagata6, Eku Shimosegawa2,7, Uwe Haberkorn5,8,9, Clemens Kratochwil5, Atsushi Shinohara2,10, Frederik Giesel2,5, Jun Hatazawa2,11. 1. Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan watabe@tracer.med.osaka-u.ac.jp. 2. Institute for Radiation Sciences, Osaka University, Osaka, Japan. 3. Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan. 4. Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Graduate School of Science, Osaka University, Osaka, Japan. 5. Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. 6. Radioisotope Research Center, Institute for Radiation Sciences, Osaka University, Osaka, Japan. 7. Department of Molecular Imaging in Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan. 8. Clinical Cooperation Unit of Nuclear Medicine, DKFZ, Heidelberg, Germany. 9. Translational Lung Research Center Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany. 10. Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan; and. 11. Research Center for Nuclear Physics, Osaka University, Osaka, Japan.
Abstract
Fibroblast activation protein (FAP), which promotes tumor growth and progression, is overexpressed in cancer-associated fibroblasts of many human epithelial cancers. Because of its low expression in normal organs, FAP is an excellent target for theranostics. In this study, we used radionuclides with relatively long half-lives, 64Cu (half-life, 12.7 h) and 225Ac (half-life, 10 d), to label FAP inhibitors (FAPIs) in mice with human pancreatic cancer xenografts. Methods: Male nude mice (body weight, 22.5 ± 1.2 g) were subcutaneously injected with human pancreatic cancer cells (PANC-1, n = 12; MIA PaCa-2, n = 8). Tumor xenograft mice were investigated after the intravenous injection of 64Cu-FAPI-04 (7.21 ± 0.46 MBq) by dynamic and delayed PET scans (2.5 h after injection). Static scans 1 h after the injection of 68Ga-FAPI-04 (3.6 ± 1.4 MBq) were also acquired for comparisons using the same cohort of mice (n = 8). Immunohistochemical staining was performed to confirm FAP expression in tumor xenografts using an FAP-α-antibody. For radioligand therapy, 225Ac-FAPI-04 (34 kBq) was injected into PANC-1 xenograft mice (n = 6). Tumor size was monitored and compared with that of control mice (n = 6). Results: Dynamic imaging of 64Cu-FAPI-04 showed rapid clearance through the kidneys and slow washout from tumors. Delayed PET imaging of 64Cu-FAPI-04 showed mild uptake in tumors and relatively high uptake in the liver and intestine. Accumulation levels in the tumor or normal organs were significantly higher for 64Cu-FAPI-04 than for 68Ga-FAPI-04, except in the heart, and excretion in the urine was higher for 68Ga-FAPI-04 than for 64Cu-FAPI-04. Immunohistochemical staining revealed abundant FAP expression in the stroma of xenografts. 225Ac-FAPI-04 injection showed significant tumor growth suppression in the PANC-1 xenograft mice, compared with the control mice, without a significant change in body weight. Conclusion: This proof-of-concept study showed that 64Cu-FAPI-04 and 225Ac-FAPI-04 could be used in theranostics for the treatment of FAP-expressing pancreatic cancer. α-therapy targeting FAP in the cancer stroma is effective and will contribute to the development of a new treatment strategy.
Fibroblast activation protein (FAP), which promotes tumor growth and progression, is overexpressed in cancer-associated fibroblasts of many human epithelial cancers. Because of its low expression in normal organs, FAP is an excellent target for theranostics. In this study, we used radionuclides with relatively long half-lives, 64Cu (half-life, 12.7 h) and 225Ac (half-life, 10 d), to label FAP inhibitors (FAPIs) in mice with human pancreatic cancer xenografts. Methods: Male nude mice (body weight, 22.5 ± 1.2 g) were subcutaneously injected with human pancreatic cancer cells (PANC-1, n = 12; MIA PaCa-2, n = 8). Tumor xenograft mice were investigated after the intravenous injection of 64Cu-FAPI-04 (7.21 ± 0.46 MBq) by dynamic and delayed PET scans (2.5 h after injection). Static scans 1 h after the injection of 68Ga-FAPI-04 (3.6 ± 1.4 MBq) were also acquired for comparisons using the same cohort of mice (n = 8). Immunohistochemical staining was performed to confirm FAP expression in tumor xenografts using an FAP-α-antibody. For radioligand therapy, 225Ac-FAPI-04 (34 kBq) was injected into PANC-1 xenograft mice (n = 6). Tumor size was monitored and compared with that of control mice (n = 6). Results: Dynamic imaging of 64Cu-FAPI-04 showed rapid clearance through the kidneys and slow washout from tumors. Delayed PET imaging of 64Cu-FAPI-04 showed mild uptake in tumors and relatively high uptake in the liver and intestine. Accumulation levels in the tumor or normal organs were significantly higher for 64Cu-FAPI-04 than for 68Ga-FAPI-04, except in the heart, and excretion in the urine was higher for 68Ga-FAPI-04 than for 64Cu-FAPI-04. Immunohistochemical staining revealed abundant FAP expression in the stroma of xenografts. 225Ac-FAPI-04 injection showed significant tumor growth suppression in the PANC-1 xenograft mice, compared with the control mice, without a significant change in body weight. Conclusion: This proof-of-concept study showed that 64Cu-FAPI-04 and 225Ac-FAPI-04 could be used in theranostics for the treatment of FAP-expressing pancreatic cancer. α-therapy targeting FAP in the cancer stroma is effective and will contribute to the development of a new treatment strategy.
Authors: Clemens Kratochwil; Frank Bruchertseifer; Hendrik Rathke; Marcus Bronzel; Christos Apostolidis; Wilko Weichert; Uwe Haberkorn; Frederik L Giesel; Alfred Morgenstern Journal: J Nucl Med Date: 2017-04-13 Impact factor: 10.057
Authors: Thomas Lindner; Anastasia Loktev; Annette Altmann; Frederik Giesel; Clemens Kratochwil; Jürgen Debus; Dirk Jäger; Walter Mier; Uwe Haberkorn Journal: J Nucl Med Date: 2018-04-06 Impact factor: 10.057
Authors: Mike Sathekge; Frank Bruchertseifer; Mariza Vorster; Ismaheel Lawal; Otto Knoesen; Johncy Mahapane; Cindy Davis; Florette Reyneke; Alex Maes; Clemens Kratochwil; Thabo Lengana; Frederik Giesel; Christophe Van de Wiele; Alfred Morgenstern Journal: J Nucl Med Date: 2019-05-17 Impact factor: 10.057
Authors: David C Blakey; F Russell Westwood; Mike Walker; Gareth D Hughes; Peter D Davis; Sue E Ashton; Anderson J Ryan Journal: Clin Cancer Res Date: 2002-06 Impact factor: 12.531
Authors: Hyung-Ok Lee; Stefanie R Mullins; Janusz Franco-Barraza; Matthildi Valianou; Edna Cukierman; Jonathan D Cheng Journal: BMC Cancer Date: 2011-06-13 Impact factor: 4.430
Authors: Anastasia Loktev; Thomas Lindner; Eva-Maria Burger; Annette Altmann; Frederik Giesel; Clemens Kratochwil; Jürgen Debus; Frederik Marmé; Dirk Jäger; Walter Mier; Uwe Haberkorn Journal: J Nucl Med Date: 2019-03-08 Impact factor: 10.057
Authors: Srikanth Boinapally; Alla Lisok; Gabriela Lofland; Il Minn; Yu Yan; Zirui Jiang; Min Jay Shin; Vanessa F Merino; Lei Zheng; Cory Brayton; Martin G Pomper; Sangeeta Ray Banerjee Journal: Eur J Nucl Med Mol Imaging Date: 2022-08-15 Impact factor: 10.057
Authors: James M Kelly; Thomas M Jeitner; Shashikanth Ponnala; Clarence Williams; Anastasia Nikolopoulou; Stephen G DiMagno; John W Babich Journal: Mol Imaging Biol Date: 2021-03-15 Impact factor: 3.488
Authors: W Nathaniel Brennen; Daniel L J Thorek; Wen Jiang; Timothy E Krueger; Lizamma Antony; Samuel R Denmeade; John T Isaacs Journal: Immunotherapy Date: 2020-11-05 Impact factor: 4.196
Authors: Christopher Montemagno; Shamir Cassim; Nicolas De Leiris; Jérôme Durivault; Marc Faraggi; Gilles Pagès Journal: Int J Mol Sci Date: 2021-06-15 Impact factor: 5.923